Grzegorz Dzida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Grzegorz Dzida has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Prystupa
Department of Internal Medicine, Medical University, Lublin, Poland
2 shared publications Anne Louise Svendsen
Department of Biostatistics & Epidemiology, Novo Nordisk A/S, Søborg, Denmark
2 shared publications- Eddy Karnieli
Endocrinology, Diabetes & Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion, Haifa, Israel
2 shared publications - Jerzy Mosiewicz
Department of Internal Diseases, Medical University, Lublin, Poland
2 shared publications - Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
2 shared publications - Paweł Kiciński
Department of Experimental Haematooncology, Medical University, Lublin, Poland
2 shared publications
Latest Publications
- Open Access
- 13 December 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (6) , 1754-1769
The Prevention Opportunities of Retinopathy in Diabetic Patients - the Position Paper endorsed by the Polish Lipid Association.
CVD prevention does not only mean effective fight against the existing cardiovascular risk factors, but also against their complications, including micro- and macrovascular ones. In relation to obesity, prediabetes and diabetes, we recognize a number of potential dangerous non-cardiovascular complications, such as neuropathy, nephropathy and retinopathy. The latter’s prevalence is even 30-40% and may appear in as many as 15% of patients with prediabetes. Not treated well might result in necessity of eye surgery or even vision loss. Fenofibrate has had a long history of evidence suggesting preventive role in primary and especially secondary prevention of retinopathy, what has been being investigated since the FIELD trial 19 years ago. In this Position Paper we have reviewed the current stage of knowledge on possible mechanisms, by which fenofibrate may contribute to retinopathy prevention, available data on safety and efficacy, to finally recommend administrating fenofibrate in prevention of this dangerous diabetic complication.
- 13 December 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (6) , 1754-1769
Open AccessThe Prevention Opportunities of Retinopathy in Diabetic Patients - the Position Paper endorsed by the Polish Lipid Association.
CVD prevention does not only mean effective fight against the existing cardiovascular risk factors, but also against their complications, including micro- and macrovascular ones. In relation to obesity, prediabetes and diabetes, we recognize a number of potential dangerous non-cardiovascular complications, such as neuropathy, nephropathy and retinopathy. The latter’s prevalence is even 30-40% and may appear in as many as 15% of patients with prediabetes. Not treated well might result in necessity of eye surgery or even vision loss. Fenofibrate has had a long history of evidence suggesting preventive role in primary and especially secondary prevention of retinopathy, what has been being investigated since the FIELD trial 19 years ago. In this Position Paper we have reviewed the current stage of knowledge on possible mechanisms, by which fenofibrate may contribute to retinopathy prevention, available data on safety and efficacy, to finally recommend administrating fenofibrate in prevention of this dangerous diabetic complication.
- Open Access
- 26 November 2023
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 28-42
Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.
- 26 November 2023
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 28-42
Open AccessPosition paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.
- Open Access
Analysis of the Diet Quality and Nutritional State of Children, Youth, and Young Adults with Prader–Willi Syndrome: A Polish Multiple Case Study
Given the lack of data on dietary quality in young individuals with Prader–Willi syndrome (PWS) in Poland, a multiple case study was conducted in which anthropometric measurements and 7-day dietary records were collected from 20 subjects with PWS. The study group consisted of 8 females and 12 males with a mean age of 14.8 years and a mean BMI of 21.6. Based on BMI analysis, five subjects were overweight, including two subjects who were obese. The study showed that 35% of the subjects had energy intakes above the recommended levels. Protein deficiency was found in one subject in the analyzed diets. However, fat intake was excessive in four subjects, and the majority exceeded the recommended intake of saturated fatty acids. Vitamin E and B12 deficiencies were found in 40% and 85% of the subjects, respectively. All subjects had inadequate intakes of vitamin D and iodine, while the majority had deficiencies in sodium and copper intakes. Calcium intake was deficient in 35% of the subjects. However, most subjects met recommendations for the intakes of other minerals, vitamins, and fiber. These findings confirm the suboptimal dietary patterns of Polish individuals with PWS, with deficits observed in the intake of certain vitamins and minerals.
Open AccessAnalysis of the Diet Quality and Nutritional State of Children, Youth, and Young Adults with Prader–Willi Syndrome: A Polish Multiple Case Study
Given the lack of data on dietary quality in young individuals with Prader–Willi syndrome (PWS) in Poland, a multiple case study was conducted in which anthropometric measurements and 7-day dietary records were collected from 20 subjects with PWS. The study group consisted of 8 females and 12 males with a mean age of 14.8 years and a mean BMI of 21.6. Based on BMI analysis, five subjects were overweight, including two subjects who were obese. The study showed that 35% of the subjects had energy intakes above the recommended levels. Protein deficiency was found in one subject in the analyzed diets. However, fat intake was excessive in four subjects, and the majority exceeded the recommended intake of saturated fatty acids. Vitamin E and B12 deficiencies were found in 40% and 85% of the subjects, respectively. All subjects had inadequate intakes of vitamin D and iodine, while the majority had deficiencies in sodium and copper intakes. Calcium intake was deficient in 35% of the subjects. However, most subjects met recommendations for the intakes of other minerals, vitamins, and fiber. These findings confirm the suboptimal dietary patterns of Polish individuals with PWS, with deficits observed in the intake of certain vitamins and minerals.
- Open Access
- 22 February 2021
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 10 (2) , 169-179
Prospektywna ocena skuteczności i bezpieczeństwa insuliny glargine 100 U / ml (Gla-100) u dorosłych chorych na cukrzycę w Polsce: badanie obserwacyjne LARE
Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM), who were recently switched from isophane (NPH) insulin. Methods. This multicenter, prospective, 52-week observational study included 321 patients with T1DM and 766 with T2DM. The primary endpoint was the percentage of participants with a HbA1c reduction of ≥ 0.5% at 52 weeks. The secondary endpoints included fasting plasma glucose (FPG) and HbA1c reduction over time, and hypoglycemic events. Results. Of the 1,087 patients included, 69.9% achieved the primary endpoint, while the mean HbA1c decreased by 1.03% and the mean FPG by 31.8 mg/dL at 52 weeks. The average annual rate of severe hypoglycemia was 0.017 events per patient-year and 0.82 events per patient-year for nocturnal hypoglycemia. The proportion of participants experiencing severe diurnal or nocturnal hypoglycemia was significantly lower in the four weeks prior to the study end than the four weeks before the switch from NPH insulin (p < 0.0001 for diurnal hypoglycemia in T1DM and < 0.002 for diurnal hypoglycemia in T2DM; p < 0.0001 for nocturnal hy-poglycemia in both T1DM and T2DM). Body weight did not change substantially throughout the study (mean increase of 0.3 kg for T1DM and 0.1 kg for T2DM). Conclusions. Patients with T1DM or T2DM in whom diabetes was not well controlled with NPH insulin treat-ment achieved better glycemic control at a lower risk of hypoglycemia after switching to Gla-100 in routine clinical practice. Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM), who were recently switched from isophane (NPH) insulin. Methods. This multicenter, prospective, 52-week observational study included 321 patients with T1DM and 766 with T2DM. The primary endpoint was the percentage of participants with a HbA1c reduction of ≥ 0.5% at 52 weeks. The secondary endpoints included fasting plasma glucose (FPG) and HbA1c reduction over time, and hypoglycemic events. Results. Of the 1,087 patients included, 69.9% achieved the primary endpoint, while the mean HbA1c decreased by 1.03% and the mean FPG by 31.8 mg/dL at 52 weeks. The average annual rate of severe hypoglycemia was 0.017 events per patient-year and 0.82 events per patient-year for nocturnal hypoglycemia. The proportion of participants experiencing severe diurnal or nocturnal hypoglycemia was significantly lower in the four weeks prior to the study end than the four weeks before the switch from NPH insulin (p < 0.0001 for diurnal hypoglycemia in T1DM and < 0.002 for diurnal hypoglycemia in T2DM; p < 0.0001 for nocturnal hy-poglycemia in both T1DM and T2DM). Body weight did not change substantially throughout the study (mean increase of 0.3 kg for T1DM and 0.1 kg for T2DM). Conclusions. Patients with T1DM or T2DM in whom diabetes was not well controlled with NPH insulin treat-ment achieved better glycemic control at a lower risk of hypoglycemia after switching to Gla-100 in routine clinical practice.
- 22 February 2021
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 10 (2) , 169-179
Open AccessProspektywna ocena skuteczności i bezpieczeństwa insuliny glargine 100 U / ml (Gla-100) u dorosłych chorych na cukrzycę w Polsce: badanie obserwacyjne LARE
Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM), who were recently switched from isophane (NPH) insulin. Methods. This multicenter, prospective, 52-week observational study included 321 patients with T1DM and 766 with T2DM. The primary endpoint was the percentage of participants with a HbA1c reduction of ≥ 0.5% at 52 weeks. The secondary endpoints included fasting plasma glucose (FPG) and HbA1c reduction over time, and hypoglycemic events. Results. Of the 1,087 patients included, 69.9% achieved the primary endpoint, while the mean HbA1c decreased by 1.03% and the mean FPG by 31.8 mg/dL at 52 weeks. The average annual rate of severe hypoglycemia was 0.017 events per patient-year and 0.82 events per patient-year for nocturnal hypoglycemia. The proportion of participants experiencing severe diurnal or nocturnal hypoglycemia was significantly lower in the four weeks prior to the study end than the four weeks before the switch from NPH insulin (p < 0.0001 for diurnal hypoglycemia in T1DM and < 0.002 for diurnal hypoglycemia in T2DM; p < 0.0001 for nocturnal hy-poglycemia in both T1DM and T2DM). Body weight did not change substantially throughout the study (mean increase of 0.3 kg for T1DM and 0.1 kg for T2DM). Conclusions. Patients with T1DM or T2DM in whom diabetes was not well controlled with NPH insulin treat-ment achieved better glycemic control at a lower risk of hypoglycemia after switching to Gla-100 in routine clinical practice. Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM), who were recently switched from isophane (NPH) insulin. Methods. This multicenter, prospective, 52-week observational study included 321 patients with T1DM and 766 with T2DM. The primary endpoint was the percentage of participants with a HbA1c reduction of ≥ 0.5% at 52 weeks. The secondary endpoints included fasting plasma glucose (FPG) and HbA1c reduction over time, and hypoglycemic events. Results. Of the 1,087 patients included, 69.9% achieved the primary endpoint, while the mean HbA1c decreased by 1.03% and the mean FPG by 31.8 mg/dL at 52 weeks. The average annual rate of severe hypoglycemia was 0.017 events per patient-year and 0.82 events per patient-year for nocturnal hypoglycemia. The proportion of participants experiencing severe diurnal or nocturnal hypoglycemia was significantly lower in the four weeks prior to the study end than the four weeks before the switch from NPH insulin (p < 0.0001 for diurnal hypoglycemia in T1DM and < 0.002 for diurnal hypoglycemia in T2DM; p < 0.0001 for nocturnal hy-poglycemia in both T1DM and T2DM). Body weight did not change substantially throughout the study (mean increase of 0.3 kg for T1DM and 0.1 kg for T2DM). Conclusions. Patients with T1DM or T2DM in whom diabetes was not well controlled with NPH insulin treat-ment achieved better glycemic control at a lower risk of hypoglycemia after switching to Gla-100 in routine clinical practice.
- Open Access
- 22 December 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 27 (4) , 568-573
Analysis of novel serum markers of fibrosis and angiogenesis in patients with alcoholic liver cirrhosis
Introduction. Alcohol consumption causes acute and chronic liver injury. The clinical forms of alcohol liver disease (ALD) include steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) associated with liver cirrhosis. Objective. The aim of the study was to determine the levels of novel markers of fibrogenesis and angiogenesis in patients with alcoholic liver cirrhosis. Serum levels of angiopoietin-like peptide 4 (ANGPTL-4), asialoglycoprotein receptor 1 (ASGP-R1), and S100 calcium-binding protein A8 (S100A8) were assessed. Levels of hyaluronic acid (Hyal) and collagen IV (Coll IV) werealso determined at various stages of alcoholic liver cirrhosis. Materials and method. The study group consisted of 72 patients with alcoholic liver cirrhosis, while the control group included 22 healthy subjects without a history of alcohol abuse. The degree of liver cirrhosis was evaluated according to the Pugh-Child criteria (Pugh-Child score). Based on thse scores, patients were assigned to one of three groups: Pugh-Child (P-Ch) A - 21 with stage A, P-Ch B - 23 with stage B and P-Ch C - 28 with stage C liver cirrhosis. Serum levels of markers were determined using ELISA. Results. The study findings demonstrated higher levels of ANGPTL-4, ASGP-R1, S100A, hyaluronic acid and serum collagen IV in the group of patients with alcoholic liver cirrhosis, compared to the control group. Furthermore, their levels increased with the progression of alcoholic liver cirrhosis. Conclusions. The biomarkers analysed in the study may be useful for diagnosis and prognosis in patients with alcoholic liver cirrhosis.
- 22 December 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 27 (4) , 568-573
Open AccessAnalysis of novel serum markers of fibrosis and angiogenesis in patients with alcoholic liver cirrhosis
Introduction. Alcohol consumption causes acute and chronic liver injury. The clinical forms of alcohol liver disease (ALD) include steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) associated with liver cirrhosis. Objective. The aim of the study was to determine the levels of novel markers of fibrogenesis and angiogenesis in patients with alcoholic liver cirrhosis. Serum levels of angiopoietin-like peptide 4 (ANGPTL-4), asialoglycoprotein receptor 1 (ASGP-R1), and S100 calcium-binding protein A8 (S100A8) were assessed. Levels of hyaluronic acid (Hyal) and collagen IV (Coll IV) werealso determined at various stages of alcoholic liver cirrhosis. Materials and method. The study group consisted of 72 patients with alcoholic liver cirrhosis, while the control group included 22 healthy subjects without a history of alcohol abuse. The degree of liver cirrhosis was evaluated according to the Pugh-Child criteria (Pugh-Child score). Based on thse scores, patients were assigned to one of three groups: Pugh-Child (P-Ch) A - 21 with stage A, P-Ch B - 23 with stage B and P-Ch C - 28 with stage C liver cirrhosis. Serum levels of markers were determined using ELISA. Results. The study findings demonstrated higher levels of ANGPTL-4, ASGP-R1, S100A, hyaluronic acid and serum collagen IV in the group of patients with alcoholic liver cirrhosis, compared to the control group. Furthermore, their levels increased with the progression of alcoholic liver cirrhosis. Conclusions. The biomarkers analysed in the study may be useful for diagnosis and prognosis in patients with alcoholic liver cirrhosis.
- Open Access
- 27 May 2020
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 14 (4) , 731-732
The Time of Uncertainty in Poland
- 27 May 2020
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 14 (4) , 731-732
Open AccessThe Time of Uncertainty in Poland
- Open Access
- 5 September 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (9) , e0221255
Obstructive sleep apnea may increase the risk of Alzheimer's disease
Amyloid-β 1–40 (Aβ 1–40) and amyloid-β 1–42 (Aβ 1–42) are the proteins known to be involved in the pathogenesis of Alzheimer’s disease (AD)–the most common cause of dementia in the elderly. Hypoxia is suspected to be one of conditions associated with Aβ plasma level increase. A common reason of hypoxia is obstructive sleep apnea (OSA), characterized by recurrent episodes of apnea. The aim of the study was to evaluate plasma Aβ 1–40 and Aβ 1–42 concentrations in patients with OSA. Patients with suspected OSA (n = 112) underwent polygraphic examinations Patients with confirmed OSA (n = 81) showed apnea/hypopnea index greater than or equal to 5. Mild and moderate form of the disease was defined when AHI was 5–30 (n = 38, OSA+), severe–when AHI was >30 (n = 43, OSA++). Individuals with AHI<5 (n = 31) served as control group (OSA-). Aβ 1–40 concentrations in OSA++ (191.1 pg/ml) group was significantly (p<0.05) higher compared with OSA- (76.9 pg/ml) and OSA+ (159.4 pg/ml) and correlated with selected parameters of hypoxemia severity. There were no differences in Aβ 1–42 concentration between the groups. In patients with severe OSA Aβ 1–40 plasma concentrations are significantly higher compared with OSA- and OSA+ and seem to be related to hypoxia severity, which may indicate increased risk of AD development in this group of patients.
- 5 September 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (9) , e0221255
Open AccessObstructive sleep apnea may increase the risk of Alzheimer's disease
Amyloid-β 1–40 (Aβ 1–40) and amyloid-β 1–42 (Aβ 1–42) are the proteins known to be involved in the pathogenesis of Alzheimer’s disease (AD)–the most common cause of dementia in the elderly. Hypoxia is suspected to be one of conditions associated with Aβ plasma level increase. A common reason of hypoxia is obstructive sleep apnea (OSA), characterized by recurrent episodes of apnea. The aim of the study was to evaluate plasma Aβ 1–40 and Aβ 1–42 concentrations in patients with OSA. Patients with suspected OSA (n = 112) underwent polygraphic examinations Patients with confirmed OSA (n = 81) showed apnea/hypopnea index greater than or equal to 5. Mild and moderate form of the disease was defined when AHI was 5–30 (n = 38, OSA+), severe–when AHI was >30 (n = 43, OSA++). Individuals with AHI<5 (n = 31) served as control group (OSA-). Aβ 1–40 concentrations in OSA++ (191.1 pg/ml) group was significantly (p<0.05) higher compared with OSA- (76.9 pg/ml) and OSA+ (159.4 pg/ml) and correlated with selected parameters of hypoxemia severity. There were no differences in Aβ 1–42 concentration between the groups. In patients with severe OSA Aβ 1–40 plasma concentrations are significantly higher compared with OSA- and OSA+ and seem to be related to hypoxia severity, which may indicate increased risk of AD development in this group of patients.
- Open Access
- 28 December 2018
- Published by VM Media Group sp. z o.o in Arterial Hypertension
- Vol. 22 (4) , 177-178
The prevalence of arterial hypertension depending on selected demographic factors among adult residents of eastern Poland district
Background. Identification and analysis of risk factors are important aspects of planning the long-term actions to prevent, early diagnose and properly treat hypertension. The aim of this study was to examine the prevalence of hypertension and to determine the relationship between the prevalence of hypertension and selected sociodemographic factors among adult residents of a typical eastern Poland district. Material and methods. The study involved 1225 residents of the Janów Lubelski district aged between 36 and 65 years. The research methodology included a questionnaire survey. Blood pressure, body weight and height were measured, the BMI was calculated. Statistical analysis was performed. Results. 26.8% of subjects are treated for hypertension. 32.9% of hypertensive subjects are treated properly and women have better control of hypertension than man (41.3% vs. 19.7%). Among subjects without treatment for hypertension, 37.5% of them have abnormally high blood pressure and it is more common in men (58.9% vs. 43.4%). The prevalence of hypertension increased with age. The percentages are from 8.6% for subjects aged 36–40 to 45.7% for subjects aged 61–65. Higher prevalence of hypertension is observed in men below the age of 50 compared to women. There is the significant rising prevalence of hypertension in women above the age of 50. The relationship between the prevalence of hypertension and the educational background is demonstrated. Among subjects with elementary education, the prevalence of hypertension is higher (45.5%) as compared to subjects with higher education (18.2%). Area of residence and marital status have no effects on the prevalence of hypertension. Conclusions. The prevalence of hypertension was lower compared to other epidemiological studies. Improvements in hypertension control have been observed for many years. The educational background has an important influence on the prevalence of hypertension. Further studies are required to establish the influence of an area of residence and marital status on the prevalence of hypertension. Background. Identification and analysis of risk factors are important aspects of planning the long-term actions to prevent, early diagnose and properly treat hypertension. The aim of this study was to examine the prevalence of hypertension and to determine the relationship between the prevalence of hypertension and selected sociodemographic factors among adult residents of a typical eastern Poland district. Material and methods. The study involved 1225 residents of the Janów Lubelski district aged between 36 and 65 years. The research methodology included a questionnaire survey. Blood pressure, body weight and height were measured, the BMI was calculated. Statistical analysis was performed. Results. 26.8% of subjects are treated for hypertension. 32.9% of hypertensive subjects are treated properly and women have better control of hypertension than man (41.3% vs. 19.7%). Among subjects without treatment for hypertension, 37.5% of them have abnormally high blood pressure and it is more common in men (58.9% vs. 43.4%). The prevalence of hypertension increased with age. The percentages are from 8.6% for subjects aged 36–40 to 45.7% for subjects aged 61–65. Higher prevalence of hypertension is observed in men below the age of 50 compared to women. There is the significant rising prevalence of hypertension in women above the age of 50. The relationship between the prevalence of hypertension and the educational background is demonstrated. Among subjects with elementary education, the prevalence of hypertension is higher (45.5%) as compared to subjects with higher education (18.2%). Area of residence and marital status have no effects on the prevalence of hypertension. Conclusions. The prevalence of hypertension was lower compared to other epidemiological studies. Improvements in hypertension control have been observed for many years. The educational background has an important influence on the prevalence of hypertension. Further studies are required to establish the influence of an area of residence and marital status on the prevalence of hypertension.
- 28 December 2018
- Published by VM Media Group sp. z o.o in Arterial Hypertension
- Vol. 22 (4) , 177-178
Open AccessThe prevalence of arterial hypertension depending on selected demographic factors among adult residents of eastern Poland district
Background. Identification and analysis of risk factors are important aspects of planning the long-term actions to prevent, early diagnose and properly treat hypertension. The aim of this study was to examine the prevalence of hypertension and to determine the relationship between the prevalence of hypertension and selected sociodemographic factors among adult residents of a typical eastern Poland district. Material and methods. The study involved 1225 residents of the Janów Lubelski district aged between 36 and 65 years. The research methodology included a questionnaire survey. Blood pressure, body weight and height were measured, the BMI was calculated. Statistical analysis was performed. Results. 26.8% of subjects are treated for hypertension. 32.9% of hypertensive subjects are treated properly and women have better control of hypertension than man (41.3% vs. 19.7%). Among subjects without treatment for hypertension, 37.5% of them have abnormally high blood pressure and it is more common in men (58.9% vs. 43.4%). The prevalence of hypertension increased with age. The percentages are from 8.6% for subjects aged 36–40 to 45.7% for subjects aged 61–65. Higher prevalence of hypertension is observed in men below the age of 50 compared to women. There is the significant rising prevalence of hypertension in women above the age of 50. The relationship between the prevalence of hypertension and the educational background is demonstrated. Among subjects with elementary education, the prevalence of hypertension is higher (45.5%) as compared to subjects with higher education (18.2%). Area of residence and marital status have no effects on the prevalence of hypertension. Conclusions. The prevalence of hypertension was lower compared to other epidemiological studies. Improvements in hypertension control have been observed for many years. The educational background has an important influence on the prevalence of hypertension. Further studies are required to establish the influence of an area of residence and marital status on the prevalence of hypertension. Background. Identification and analysis of risk factors are important aspects of planning the long-term actions to prevent, early diagnose and properly treat hypertension. The aim of this study was to examine the prevalence of hypertension and to determine the relationship between the prevalence of hypertension and selected sociodemographic factors among adult residents of a typical eastern Poland district. Material and methods. The study involved 1225 residents of the Janów Lubelski district aged between 36 and 65 years. The research methodology included a questionnaire survey. Blood pressure, body weight and height were measured, the BMI was calculated. Statistical analysis was performed. Results. 26.8% of subjects are treated for hypertension. 32.9% of hypertensive subjects are treated properly and women have better control of hypertension than man (41.3% vs. 19.7%). Among subjects without treatment for hypertension, 37.5% of them have abnormally high blood pressure and it is more common in men (58.9% vs. 43.4%). The prevalence of hypertension increased with age. The percentages are from 8.6% for subjects aged 36–40 to 45.7% for subjects aged 61–65. Higher prevalence of hypertension is observed in men below the age of 50 compared to women. There is the significant rising prevalence of hypertension in women above the age of 50. The relationship between the prevalence of hypertension and the educational background is demonstrated. Among subjects with elementary education, the prevalence of hypertension is higher (45.5%) as compared to subjects with higher education (18.2%). Area of residence and marital status have no effects on the prevalence of hypertension. Conclusions. The prevalence of hypertension was lower compared to other epidemiological studies. Improvements in hypertension control have been observed for many years. The educational background has an important influence on the prevalence of hypertension. Further studies are required to establish the influence of an area of residence and marital status on the prevalence of hypertension.
- Open Access
- 4 April 2018
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 7 (2) , 97-101
Type 2 diabetes in patients older than 70 years — aspects of metabolic control
Background. The differences in the clinical manifestation and course of diabetes observed in older individuals should translate into various options of treatment and management of the elderly diabetic patients. Of particular importance is the early detection of disease complications due to its impact on the physical and mental health of elderly patients. Material and methods. All participants were hospitalised in the Department of Internal Medicine, University Hospital No. 1 between the year 2012–2016. Based on the medical records, the consecutively presenting patients diagnosed with type 2 diabetes were divided into three basic groups: group 1 aged 37–58 years (30 individuals), group 2 aged 70–79 years (30 individuals) and group 3 aged ≥ 80 years (50 individuals). The exclusion criteria were lack of logical verbal contact and substantial impairment of physical activity verified with the Katz Basic Activities of Daily Living (ADL) scale. Based on the medical history and documentation, the duration of diabetes, the BMI and frequency of hypoglycaemia were established. Among patients, as part of their stay and regardless of the study conducted, the main parameters were determined referring to metabolic control of type 2 diabetes mellitus (percentage of glycated haemoglobin, lipid profile) and blood pressure measurement. Results. The particular groups of patients differed in terms of the mean disease duration (p < 0.001), i.e. 5 ± 6.4 years in group 1, 16.1 ± 8.6 years in group 2 and 14.6 ± 9 years in group 3. There were statistically significant inter-group differences in mean body weight (BW) and BMI (patients ≥ 80: BW — 70.7 ± 14.3 (kg), BMI: 27.5 ± 4.3 (kg/m2); 70–79 years of age group: BW: 77.1 ± 16.4 (kg), BMI: 28.9 ± 6 (kg/m2); group 1 (BW: 92.4 ± 21.4 (kg), BMI: 31.5 ± 7.0 (kg/m2). The best glucose control was observed amongst patients ≥ 80 (group 3), as compared to group 1 — 47 patients (84%) vs. 4 patients (13.3%) (p < 0.001). The percentages of HbA1c were as follows: 8.7 ± 2.3 (%) in group 1, 7.3 ± 1.2 (%) in group 2 and 6.9 ± 0.9 in group 3, respectively (p < 0.001). There were no statistically significant differences in the blood pressure between particular groups of patients. Hypoglycaemia did not occur more frequently in any of the studied groups. Conclusions. Elderly patients suffering from type 2 diabetes vary in numerous aspects from younger patients. The basic differences were observed in relation to anthropometric indices and average duration of the disease. Treatment of type 2 diabetes in elderly patients leads to excessive control with respect to the carbohydrate metabolism although patients do not report hypoglycaemia more frequently. Background. The differences in the clinical manifestation and course of diabetes observed in older individuals should translate into various options of treatment and management of the elderly diabetic patients. Of particular importance is the early detection of disease complications due to its impact on the physical and mental health of elderly patients. Material and methods. All participants were hospitalised in the Department of Internal Medicine, University Hospital No. 1 between the year 2012–2016. Based on the medical records, the consecutively presenting patients diagnosed with type 2 diabetes were divided into three basic groups: group 1 aged 37–58 years (30 individuals), group 2 aged 70–79 years (30 individuals) and group 3 aged ≥ 80 years (50 individuals). The exclusion criteria were lack of logical verbal contact and substantial impairment of physical activity verified with the Katz Basic Activities of Daily Living (ADL) scale. Based on the medical history and documentation, the duration of diabetes, the BMI and frequency of hypoglycaemia were established. Among patients, as part of their stay and regardless of the study conducted, the main parameters were determined referring to metabolic control of type 2 diabetes mellitus (percentage of glycated haemoglobin, lipid profile) and blood pressure measurement. Results. The particular groups of patients differed in terms of the mean disease duration (p < 0.001), i.e. 5 ± 6.4 years in group 1, 16.1 ± 8.6 years in group 2 and 14.6 ± 9 years in group 3. There were statistically significant inter-group differences in mean body weight (BW) and BMI (patients ≥ 80: BW — 70.7 ± 14.3 (kg), BMI: 27.5 ± 4.3 (kg/m2); 70–79 years of age group: BW: 77.1 ± 16.4 (kg), BMI: 28.9 ± 6 (kg/m2); group 1 (BW: 92.4 ± 21.4 (kg), BMI: 31.5 ± 7.0 (kg/m2). The best glucose control was observed amongst patients ≥ 80 (group 3), as compared to group 1 — 47 patients (84%) vs. 4 patients (13.3%) (p < 0.001). The percentages of HbA1c were as follows: 8.7 ± 2.3 (%) in group 1, 7.3 ± 1.2 (%) in group 2 and 6.9 ± 0.9 in group 3, respectively (p < 0.001). There were no statistically significant differences in the blood pressure between particular groups of patients. Hypoglycaemia did not occur more frequently in any of the studied groups. Conclusions. Elderly patients suffering from type 2 diabetes vary in numerous aspects from younger patients. The basic differences were observed in relation to anthropometric indices and average duration of the disease. Treatment of type 2 diabetes in elderly patients leads to excessive control with respect to the carbohydrate metabolism although patients do not report hypoglycaemia more frequently.
- 4 April 2018
- Published by VM Media Group sp. z o.o in Clinical Diabetology
- Vol. 7 (2) , 97-101
Open AccessType 2 diabetes in patients older than 70 years — aspects of metabolic control
Background. The differences in the clinical manifestation and course of diabetes observed in older individuals should translate into various options of treatment and management of the elderly diabetic patients. Of particular importance is the early detection of disease complications due to its impact on the physical and mental health of elderly patients. Material and methods. All participants were hospitalised in the Department of Internal Medicine, University Hospital No. 1 between the year 2012–2016. Based on the medical records, the consecutively presenting patients diagnosed with type 2 diabetes were divided into three basic groups: group 1 aged 37–58 years (30 individuals), group 2 aged 70–79 years (30 individuals) and group 3 aged ≥ 80 years (50 individuals). The exclusion criteria were lack of logical verbal contact and substantial impairment of physical activity verified with the Katz Basic Activities of Daily Living (ADL) scale. Based on the medical history and documentation, the duration of diabetes, the BMI and frequency of hypoglycaemia were established. Among patients, as part of their stay and regardless of the study conducted, the main parameters were determined referring to metabolic control of type 2 diabetes mellitus (percentage of glycated haemoglobin, lipid profile) and blood pressure measurement. Results. The particular groups of patients differed in terms of the mean disease duration (p < 0.001), i.e. 5 ± 6.4 years in group 1, 16.1 ± 8.6 years in group 2 and 14.6 ± 9 years in group 3. There were statistically significant inter-group differences in mean body weight (BW) and BMI (patients ≥ 80: BW — 70.7 ± 14.3 (kg), BMI: 27.5 ± 4.3 (kg/m2); 70–79 years of age group: BW: 77.1 ± 16.4 (kg), BMI: 28.9 ± 6 (kg/m2); group 1 (BW: 92.4 ± 21.4 (kg), BMI: 31.5 ± 7.0 (kg/m2). The best glucose control was observed amongst patients ≥ 80 (group 3), as compared to group 1 — 47 patients (84%) vs. 4 patients (13.3%) (p < 0.001). The percentages of HbA1c were as follows: 8.7 ± 2.3 (%) in group 1, 7.3 ± 1.2 (%) in group 2 and 6.9 ± 0.9 in group 3, respectively (p < 0.001). There were no statistically significant differences in the blood pressure between particular groups of patients. Hypoglycaemia did not occur more frequently in any of the studied groups. Conclusions. Elderly patients suffering from type 2 diabetes vary in numerous aspects from younger patients. The basic differences were observed in relation to anthropometric indices and average duration of the disease. Treatment of type 2 diabetes in elderly patients leads to excessive control with respect to the carbohydrate metabolism although patients do not report hypoglycaemia more frequently. Background. The differences in the clinical manifestation and course of diabetes observed in older individuals should translate into various options of treatment and management of the elderly diabetic patients. Of particular importance is the early detection of disease complications due to its impact on the physical and mental health of elderly patients. Material and methods. All participants were hospitalised in the Department of Internal Medicine, University Hospital No. 1 between the year 2012–2016. Based on the medical records, the consecutively presenting patients diagnosed with type 2 diabetes were divided into three basic groups: group 1 aged 37–58 years (30 individuals), group 2 aged 70–79 years (30 individuals) and group 3 aged ≥ 80 years (50 individuals). The exclusion criteria were lack of logical verbal contact and substantial impairment of physical activity verified with the Katz Basic Activities of Daily Living (ADL) scale. Based on the medical history and documentation, the duration of diabetes, the BMI and frequency of hypoglycaemia were established. Among patients, as part of their stay and regardless of the study conducted, the main parameters were determined referring to metabolic control of type 2 diabetes mellitus (percentage of glycated haemoglobin, lipid profile) and blood pressure measurement. Results. The particular groups of patients differed in terms of the mean disease duration (p < 0.001), i.e. 5 ± 6.4 years in group 1, 16.1 ± 8.6 years in group 2 and 14.6 ± 9 years in group 3. There were statistically significant inter-group differences in mean body weight (BW) and BMI (patients ≥ 80: BW — 70.7 ± 14.3 (kg), BMI: 27.5 ± 4.3 (kg/m2); 70–79 years of age group: BW: 77.1 ± 16.4 (kg), BMI: 28.9 ± 6 (kg/m2); group 1 (BW: 92.4 ± 21.4 (kg), BMI: 31.5 ± 7.0 (kg/m2). The best glucose control was observed amongst patients ≥ 80 (group 3), as compared to group 1 — 47 patients (84%) vs. 4 patients (13.3%) (p < 0.001). The percentages of HbA1c were as follows: 8.7 ± 2.3 (%) in group 1, 7.3 ± 1.2 (%) in group 2 and 6.9 ± 0.9 in group 3, respectively (p < 0.001). There were no statistically significant differences in the blood pressure between particular groups of patients. Hypoglycaemia did not occur more frequently in any of the studied groups. Conclusions. Elderly patients suffering from type 2 diabetes vary in numerous aspects from younger patients. The basic differences were observed in relation to anthropometric indices and average duration of the disease. Treatment of type 2 diabetes in elderly patients leads to excessive control with respect to the carbohydrate metabolism although patients do not report hypoglycaemia more frequently.
- Open Access
- 1 October 2015
- Published by Elsevier in Primary Care Diabetes
- Vol. 9 (5) , 346-353
Depressive symptoms prior to and following insulin initiation in patients with type 2 diabetes mellitus: Prevalence, risk factors and effect on physician resource utilisation
- 1 October 2015
- Published by Elsevier in Primary Care Diabetes
- Vol. 9 (5) , 346-353
Open AccessDepressive symptoms prior to and following insulin initiation in patients with type 2 diabetes mellitus: Prevalence, risk factors and effect on physician resource utilisation